Asia
During the past two years, fundraising and investment in biotechnology have reached record levels.
In a late-breaking presentation on Saturday, EQRx and partner CStone Pharmaceuticals will report data from the phase III GEMSTONE-301 study of its anti-PD-L1 antibody sugemalimab.
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Hong Kong-based Prenetics Group Limited, a medical diagnostic startup, is making its debut on the Nasdaq through a merger with Artisan Acquisitions Corp. The deal is valued at $1.25 billion.
Biopharma and life sciences companies and organizations from across the globe provide updates on their businesses and pipelines.
Data coming in about the COVID-19 pandemic shows some promising overall trends, with other more disturbing ones, particularly in breakthrough infections of the fully vaccinated.
A patient treated with Astellas Pharma’s experimental gene therapy for patients with X-linked Myotubular Myopathy (XLMTM) has died after a serious adverse event following treatment.
This newfound ability to take tumor cells directly from a patient and incorporate them into a more clinically accurate glioblastoma model could lead to greater patient personalization in cancer therapeutics.
Everest will pay Providence $50 million in cash upfront for access to its COVID-19 vaccine and other mRNA vaccine candidates targeting specific variants in earlier stages of development.
PRESS RELEASES